Leuprolide is a synthetic gonadotropin-releasing hormone (GnRH) agonist and a peptide-based active pharmaceutical ingredient used in hormone-dependent medical conditions. It is structurally related to naturally occurring GnRH but has been modified to provide increased stability and prolonged biological activity.
Leuprolide initially stimulates the pituitary GnRH receptors, causing an increase in luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous administration, however, persistent GnRH receptor stimulation results in downregulation and desensitization of pituitary GnRH receptors, leading to suppression of LH and FSH secretion and a substantial reduction in gonadal sex-hormone production.
Leuprolide is a synthetic decapeptide with the molecular formula C59H84N16O12 and a molecular weight of approximately 1209.40 g/mol. Its CAS Number is 53714-98-4.
Leuprolide is generally formulated as a peptide pharmaceutical and may be supplied in different pharmaceutical forms, including leuprolide acetate. Because it is a peptide, its quality evaluation involves peptide identity, purity, related peptides and biological activity in addition to conventional pharmaceutical testing.
Leuprolide acts as a potent GnRH receptor agonist.
During continuous administration, it initially increases LH and FSH secretion. Continued stimulation causes pituitary GnRH receptor desensitization, resulting in decreased LH and FSH release. Consequently, production of testosterone in males and estrogen in females is suppressed.
This mechanism is responsible for its therapeutic use in several hormone-dependent conditions, including prostate cancer, endometriosis and uterine fibroids, as well as for suppression of gonadal function in specific clinical applications.
Leuprolide is used in hormone-dependent conditions, including advanced prostate cancer, endometriosis and uterine fibroids. It is also used in certain reproductive medicine protocols and for central precocious puberty in appropriate formulations and patient populations.
The specific indication, dosage form and treatment regimen depend on the approved pharmaceutical product and applicable regulatory requirements.
Leuprolide API requires peptide-specific analytical characterization. Testing may include identity, peptide purity, assay, related peptides, degradation products, water content, residual solvents, elemental impurities and microbial quality attributes where applicable.
Analytical methods may include HPLC, peptide mapping, mass spectrometry, amino-acid analysis and other validated chromatographic or spectroscopic procedures. Biological activity or receptor-based potency testing may also be applicable.
Acceptance criteria should be based on the applicable approved manufacturer's drug-substance specification, Certificate of Analysis and relevant regulatory requirements.
Leuprolide should be stored according to the approved storage conditions for the specific peptide drug substance or formulation. Temperature control, protection from moisture and light, and avoidance of conditions that may cause peptide degradation are important.
Specific storage and transportation requirements should always follow the applicable manufacturer's approved specification.
Leuprolide API may be supplied for qualified pharmaceutical manufacturing, peptide formulation development, analytical and research applications, subject to applicable quality and regulatory requirements.
Leuprolide API is available for qualified pharmaceutical and biopharmaceutical development requirements subject to applicable quality and regulatory standards. Customers can request product specifications, Certificate of Analysis, analytical documentation, packaging information and commercial details according to their requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | ≤ 0.5% |
| Total Impurities | ≤ 1.5% |
| Water Content | NMT 1.0% |